At Pfizer Biotherapeutics Research, we're not content waiting to witness the evolution of our industry. Instead, we are building on our current successes and capabilities, with a goal of developing the most compelling story of biotherapeutic scientific discoveries - and through this a compelling portfolio of biological therapies.

Our emphasis on innovation in Biotherapeutics has brought to market a wide range of ground-breaking medicines, such as Fragmin, Genotropin, Macugen, Somavert and our first-in-class inhaled insulin product Exubera. Our accomplishments, to date, make us the eighth-largest biotech in the world with an anticipated $1.5 billion in sales. But there is much more work to be done, and we are staged to deliver on our challenging goals with a blossoming pipeline.

Playing an integral part of the Biotherapeutics line in Pfizer Research is Vaccines Research. The vaccines research departments in Sandwich, UK and La Jolla, CA seek to discover novel vaccines (prophylactic and therapeutic) for the prevention and treatment of significant human diseases (infectious diseases, oncology, CNS and Allergy and Respiratory) using a variety of vaccines technology platforms combined with immunomodulatory agents.

Another essential part of Biotherapeutics Research is Rinat PGRD, which is comprised of skilled protein engineers, pharmacologists and biochemists that have expertise in developing novel protein-based therapeutics. Rinat is currently collaborating with other PGRD sites to conduct research that addresses significant unmet medical needs in Neurology, Oncology, Infectious Disease and Cardiovascular, Metabolic and Endocrine Diseases.

The Research team in St. Louis, MO also plays a key role in Biotherapeutics by focusing on the generation of novel therapeutic proteins, aptamers, and antibodies to treat diseases in numerous therapeutic areas. The St. Louis scientists, using key strategic alliances with Medarex, MorphoSys, Archemix and Noxxon, work in a collaborative fashion with Pfizer Research sites around the globe to deliver both monoclonal antibodies and macromolecular therapeutics. Additionally, one of the key research interests in St. Louis is applying protein engineering to support improving pharmaceutic properties of Biotherapeutics.

For more information, visit www.pfizerbiotherapeutics.com

Playing a key role in the discovery and development of new medicines is Pfizer Worldwide Comparative Medicine (WWCM). In WWCM, we apply our knowledge and expertise in laboratory animal science in a dynamic pharmaceutical environment under controlled laboratory conditions, while assuring that these animals are used in an appropriate and humane manner.

Here you will find the resources that enable the flawless delivery of animal care and welfare programs while also developing expertise to expand our research portfolio. The research accomplished in this field - key translational discovery and development findings - plays a vital role in enhancing the strategic alignment of PGRD's global mission.

PGRD's research organization has six Centers of Emphasis: biology, chemistry, chemistry sourcing, computational sciences, innovation and idea farm, and global indications discovery unit (IDU). Each center functions in collaboration with the other centers, each with its own dedicated purpose.

The biology segment focuses on biology sourcing, bioimaging, genetically modified models and reagent antibodies; chemistry deals with high-throughput screening, liquid storage and DNA and biofluids, as part of the BioBank; chemistry sourcing manages external chemistry resources; computational sciences delivers computational methods and tools used throughout research; innovation and idea farm provides software-enabled collaborative problem-solving and innovation-facilitation across PGRD and outside to partners; and global IDU addresses the immediate business priorities of Pfizer by delivering additional phase II starts.

Through the innovation and cooperation of our six research arms, PGRD has built — and continues to develop — a robust research pipeline aimed at each of our 11 therapeutic areas: Allergy & Respiratory; Cardiovascular, Metabolic, and Endocrine Diseases; Dermatology; Gastrointestinal & Hepatology; Genitourinary; Infectious Diseases; Inflammation; Neuroscience; Oncology; Opthalmology; and Pain.

Pfizer's RTC hub in Cambridge, MA is imperative to the progress of our Centers of Emphasis. Without the constraints of a therapeutic area portfolio, we're applying cutting-edge techniques and technologies with broad utility across different therapeutic areas — developing a deep knowledge of new drug discovery targets, novel chemical structures, and potential safety liabilities. At the RTC, we're balancing the strength of Pfizer R&D with the nimble feel of a small biotech, and creating an exciting and team-based scientific environment for over 150 colleagues with a wide range of scientific skills and experience. Collaboration and cooperation are the norm here. And the unique working environment — truly a small biotech with the backing of the largest research budget in the industry — is allowing science to leap forward into the future and bring to market what are miracles for many.

Our Research Chemistry group focuses on designing the chemical matter and synthesizing organic molecules for biological evaluation. Working in state-of-the-art facilities, our chemists synthesize organic molecules with potential biological activity, prepare intermediates for the synthesis of these molecules, and develop new methods of synthesis.

The role of chemistry research in new drug research begins with finding lead compounds that have an effect on the target disease, and to ultimately find a candidate compound and advance it to the next stage of evaluation. Diverse technologies are needed to accomplish this, including surveys of compound databases, compound design and hypothetical screening that uses computational chemistry, organic synthesis methods, parallel synthesis that uses a combination of robotics and the latest synthesis technology to synthesize different types of compounds in a short time, and compound analysis. In addition, it is necessary to analyze data obtained from the biology and metabolism research groups, and incorporate them into the compound designs.

Our group also applies modern techniques of organic synthesis including a variety of organic reactions at several scales, inert atmosphere techniques, medium-speed analoging, thin-layer chromatography, NMR, LCMS, MS, flash chromatography, re-crystallization, and distillation.

For more information, visit www.pfizerresearchchemistry.com

The role of Research Biology is vital in creating breakthroughs, the primary functions being to determine the rationale for our drugs and cover the vast spectrum of discovery research. This includes seeking out at the genetic level the mechanism believed to be involved in the target disease and establishing an experimental regime that can screen large amounts of compounds; establishing an in vitro experimental regime that will uncover the lead compound and using it to collect and analyze data on the compound; and establishing an in vivo model regime to verify whether there is actually an effect on the disease.

For more information, visit www.pfizerresearchbiology.com

Pfizer Pharmacokinetics, Dynamics, and Metabolism (PDM) is the largest drug metabolism and pharmokinetics group in the world. With over $100 MM per year invested in the latest research and technology, PDM plays a critical part in both drug discovery and drug development — its primary role being the characterization of the effects of the body on potential drug entities ranging from chemically synthesized small molecules to biologically derived macromolecules. Core competencies include: in vitro and in vivo ADME research (transporters and metabolism), biologics research, bioanalytical science and automation, PK/PD modeling and biomarkers, and in silico and computational modeling.

For more information, visit www.pfizerdrugmetabolism.com